ReviewInternational urology and nephrology2025
Molecular frontiers in hemodialysis: unraveling the role of membranes in gene expression, epigenetics, and inflammatory pathways.
Review in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemodialysis (HD) remains a vital treatment for patients with end-stage kidney disease, yet the characteristics of dialysis membranes significantly influence therapeutic outcomes. Membrane fouling, often caused by protein adherence, reduces toxin clearance and may lead to fluid and electrolyte imbalances. Recent studies have focused on modifying membrane chemistry to improve biocompatibility and reduce fouling. Although advancements have been made in understanding the biochemical and inflammatory responses during HD, the underlying molecular mechanisms, especially those involving epigenetic regulation remain incompletely understood. This review explores recent progress in HD treatment, with a specific emphasis on inflammation, gene expression, and epigenetic alterations. We examine how pro-inflammatory cytokines activate transcription factors that regulate gene expression and how genetic variability within inflammatory genes adds complexity to these pathways. In parallel, we assess emerging biocompatible membrane technologies designed to reduce adverse interactions with blood components, thereby enhancing patient safety and treatment efficiency. In addition, we discuss how genetic and epigenetic changes such as DNA mutations, methylation patterns, and histone modifications may influence patient responses to HD and contribute to complications, including mental health disorders such as depression. These insights support the development of personalized HD strategies tailored to the molecular and genetic profiles of individual patients. By integrating current findings from genetics, epigenetics, and gene expression studies, this review provides a comprehensive perspective on HD-related inflammation and molecular dysregulation. Our goal is to highlight key interconnections and identify critical knowledge gaps that must be addressed to improve long-term outcomes and quality of life for HD patients.
Indexed as
Identifiers
40560524What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.